Back to Search

A Phase II Study of sEphB4-HSA in Kaposi Sarcoma

  • Protocol Number: 201510016
  • Principal Investigator: Ratner, Lee
  • Cancer Types: Sarcoma

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

This phase II trial studies recombinant EphB4-HSA fusion protein (EphB4-HSA) in treating patients with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that provide blood to the cancer, and may also prevent cancer cells from growing.

Protocol Interventions

Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Recombinant EphB4-HSA Fusion Protein